Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age40-60
SponsorWashington State University
About this trial
The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Eligibility criteria
Qualifiers
designated female at birth
40-60 years of age
able to give informed consent (no intellectual disability)
stable pharmacotherapeutic regimen, no change in the past 3 months
Disqualifiers
currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication
severe depression, neurovegetative symptoms, or current suicidality
psychosis or family history of psychosis
pregnant or breastfeeding
Trial design
Treatments tested in this trial
- Hemp-derived cannabinoids
- Placebo
Treatment groups
104 Participants
are divided into 2 treatment groupsSponsors and collaborators
Washington State University
Lead sponsor
Terra Mater Botanicals Pty Ltd
Collaborator
Source ClinicalTrials.gov